CHM.AX stock up 25% at ASX close 06 Feb 2026: small-cap biotech rally to monitor

CHM.AX stock led gains on the ASX at market close on 06 Feb 2026, rising 25.00% to A$0.0025 on unusually focused buying. Trading volume was 626,114 shares, below the 50-day average but enough to push the micro‑cap higher from an open of A$0.0020. Investors reacted to recent clinical updates and sector comparisons, sending Chimeric Therapeutics Limited (CHM.AX) into the top-gainers list in the Healthcare Biotechnology group. We break down why the move happened, what it means for valuation, and short-term risks ahead.

CHM.AX stock: today’s price action and drivers

CHM.AX stock closed at A$0.0025, a A$0.0005 gain on the day after opening at A$0.0020. The move lifted the year-to-date change to 25.00% while the one-year change remains -58.33%, reflecting high volatility in the ASX small‑cap biotech cohort. Volume at 626,114 was light versus the average of 6,007,948, suggesting price moves were driven by targeted orders rather than broad market rotation. Clinical progress in CHM 0201 and CHM 1101 programs is the likeliest headline catalyst given the company’s pipeline focus.

CHM.AX stock: fundamentals, market cap and financials

Chimeric Therapeutics Limited (CHM.AX) is a clinical‑stage biotechnology company listed on the ASX with market capitalisation of A$11,046,759 and 4,418,703,619 shares outstanding. Reported EPS is -0.01 and trailing PE is negative at -0.25, consistent with pre‑commercial biotech peers. Key ratios show a price-to-sales of 1.21 and price-to-book of 2.14, while the current ratio of 0.72 highlights limited short-term liquidity. These metrics underline a speculative equity profile where pipeline milestones typically drive re‑rating.

CHM.AX stock: Meyka AI grade and valuation context

Meyka AI rates CHM.AX with a score out of 100: 66.15 / B (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating data shows mixed signals: a DCF sub-score suggesting upside while return metrics and coverage ratios flag risk. Investors should treat the Meyka grade as a data-driven snapshot, not personalised advice.

CHM.AX stock: technicals and trading outlook

Technical indicators for CHM.AX stock show an RSI of 39.73, indicating the stock is not yet overbought after the gain. The 50-day average price is A$0.0027 and 200-day average is A$0.00355, both above today’s close, signalling longer-term downtrend pressure. On‑chain volume indicators show low relative volume (relVolume 0.02), which increases sensitivity to single large trades. Given the thin liquidity, stop placement and position sizing are critical for traders.

CHM.AX stock: sector comparison and risk factors

CHM.AX stock sits in the Healthcare Biotechnology industry, where the ASX sector average current ratio is 3.85 and average PB is 5.07. Chimeric’s cash per share of 0.00340 and operating cash flow per share of -0.00293 show a funding runway risk if pipelines require extended trials. High dilution risk exists: weighted average shares grew materially in recent periods. Clinical trial timelines, regulatory readouts and funding events remain the most significant near-term risks and opportunity drivers.

CHM.AX stock: catalysts, news flow and where to watch next

Key near-term catalysts for CHM.AX stock include scheduled earnings or R&D updates and the company’s planned announcements around CHM 0201 and CHM 1101 programmes. The next earnings announcement date is flagged for 26 Feb 2026, which could reset expectations. Monitor ASX filings and sector news; external coverage and peer comparisons on platforms like Investing.com may amplify moves source and source. For live quotes and position tracking use our Meyka AI‑powered market analysis tools at Meyka CHM.AX page.

Final Thoughts

Short-term momentum put CHM.AX stock among the ASX top gainers on 06 Feb 2026, but the move is driven by low liquidity and news sensitivity rather than sustained volume. Meyka AI’s forecast model projects A$0.0100 within the next quarter, which compared with the current price of AUD 0.0025 implies an upside of 300.00%. That forecast is model-based and assumes successful trial progress and funding; it is not a guarantee. Balance the potential upside against clear risks: negative EPS (-0.01), cash constraints, and historic share dilution. For portfolio use, treat CHM.AX stock as speculative exposure within a diversified biotech sleeve and size positions for high volatility. Track upcoming ASX announcements and peer biotech moves that could validate or reverse today’s gain.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.